Advances in Microfluidic 3D Cell Culture for Preclinical Drug Development
Overview
Affiliations
Drug development is often a very long, costly, and risky process due to the lack of reliability in the preclinical studies. Traditional current preclinical models, mostly based on 2D cell culture and animal testing, are not full representatives of the complex in vivo microenvironments and often fail. In order to reduce the enormous costs, both financial and general well-being, a more predictive preclinical model is needed. In this chapter, we review recent advances in microfluidic 3D cell culture showing how its development has allowed the introduction of in vitro microphysiological systems, laying the foundation for organ-on-a-chip technology. These findings provide the basis for numerous preclinical drug discovery assays, which raise the possibility of using micro-engineered systems as emerging alternatives to traditional models, based on 2D cell culture and animals.
Miao X, Wu X, You W, He K, Chen C, Pathak J J Transl Med. 2024; 22(1):810.
PMID: 39218900 PMC: 11367938. DOI: 10.1186/s12967-024-05451-w.
Engineering models of head and neck and oral cancers on-a-chip.
da Costa Sousa M, Vignolo S, Franca C, Mereness J, Alves Fraga M, Silva-Sousa A Biomicrofluidics. 2024; 18(2):021502.
PMID: 38464668 PMC: 10919958. DOI: 10.1063/5.0186722.
Ly K, Rajtboriraks M, Elgerbi A, Luo X, Raub C Adv Healthc Mater. 2024; 13(14):e2302970.
PMID: 38351394 PMC: 11144107. DOI: 10.1002/adhm.202302970.
Application of three-dimensional cell culture technology in screening anticancer drugs.
Sun Y, Ma H Biotechnol Lett. 2023; 45(9):1073-1092.
PMID: 37421554 DOI: 10.1007/s10529-023-03410-x.
Spheroid Engineering in Microfluidic Devices.
Tevlek A, Kecili S, Ozcelik O, Kulah H, Tekin H ACS Omega. 2023; 8(4):3630-3649.
PMID: 36743071 PMC: 9893254. DOI: 10.1021/acsomega.2c06052.